We are so pleased to announce our partnership with KYOWA Pharmaceutical Industry Co. Ltd, to manufacture a generic product for filling in Japan.
KYOWA Pharmaceutical Industry Co. Ltd., a premier Japanese pharmaceutical company, has contracted with Bora Pharmaceutical Laboratories Inc. (Zhunan), a division of Bora Pharmaceuticals for the manufacturing of generic product for filing in Japan. KYOWA will be the first Japanese client for Bora’s Zhunan manufacturing site which is already USFDA, MHRA, and TFDA approved.
KYOWA Pharmaceutical Industry Co. Ltd., a premier Japanese pharmaceutical company, has contracted with Bora Pharmaceutical Laboratories Inc. (Zhunan), a division of Bora Pharmaceuticals for the manufacturing of generic products with later filling in Japan. KYOWA will be the first Japanese client for Bora's Zhunan manufacturing site which is already USFDA, MHRA, and TFDA approved.
India’s Lupin Ltd is in advanced talks to sell its Japanese generics subsidiary Kyowa Pharmaceuticals for an enterprise value of $600 million to a local player as it steps up efforts to significantly cut operations in the world’s third largest pharma market. The name of the buyer could not be independently verified. People close to the discussions said that an announcement is expected in November.
Drug major Lupin LtdBSE 0.63 % today said its Japanese subsidiary Kyowa Pharmaceutical Industry Co Ltd has entered into an agreement with Astellas Pharma Inc for exclusive right to distribute and promote extended-release tablets of quetiapine fumarate in Japan.
Leading Japanese drugmakers have inked a collaboration pact that will see national clinics and research arms provide cell and tissue samples in a program focused on new therapies in 5 areas as diverse as immunotherapy and depression.nnThe effort funded with ¥3 billion starting in Japan's 2019 fiscal year sees Astellas Pharma, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharmaceutical and Chugai Pharmaceutical all join with the National Cancer Center, the National Center for Global Health and Medicine, and the Agency for Medical Research and Development, according to the Nikkei Asian Review.
Takeda is going behind closed doors with its first DTC campaign for Entyvio, a new biologic treatment for inflammatory bowel diseases. Bathroom doors, that is.